Systemic inhibition of soluble TNF significantly changes glial cell populations leading to improved myelin integrity and better functional outcome after experimental stroke
https://www.gubra.dk/wp-content/uploads/2025/07/.pdf
Proof-of-concept testing of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
Background & aim: The long-acting glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved for the treatment of type 2 diabetes and obesity. Recently, semaglutide has been reported to improve liver histopathological outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis…
Superior Hepatoprotective Effects of OPK-88006, a Novel GLP-1/Glucagon receptor dual agonist, to Semaglutide and Survodutide in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH
Background & aim: OPK-88006 is a novel peptide-based, long-acting glucagon-like peptide-1 receptor (GLP1R)/glucagon receptor (GCGR) dual agonist in current preclinical development for metabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH). The present study aimed to compare the therapeutic profile…
Tirzepatide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH-HCC with advanced fibrosis
Background & aim: The glucagon-like peptide-1 receptor (GLP1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist tirzepatide is currently approved for the treatment of obesity and type 2 diabetes. In a recent phase 2b trial (SYNERGY-NASH) in patients with metabolic-dysfunction…
Molecular Hallmarks of Lung Cellular Senescence in the Repetitive Bleomycin-induced and Spirometry-confirmed Mouse Model of IPF
Background & aim: Growing evidence suggests that senescent cells contribute to the development and progression of idiopathic pulmonary fibrosis (IPF). This study aimed to identify and characterize key markers of lung senescence using a repetitive bleomycin-induced (BLEO), spirometry-confirmed mouse model…
Automated AI-assisted Ashcroft scoring of lung fibrosis in spirometry-confirmed and bleomycin-induced mouse model of IPF
Background & aim: Clinically derived Ashcroft scoring of lung fibrosis is commonly applied to preclinical models of idiopathic pulmonary fibrosis (IPF). As for any manual, semiquantitative histopathological scoring system, Ashcroft scoring is prone to inter- and intra-observer variability which influences…
Comparative anti-fibrotic efficacy of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
Background & aim: Resmetirom (RES, THR-βR agonist) has recently been FDA-approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Other drug concepts are in late-stage clinical development for MASH, including semaglutide (SEMA, GLP1R agonist), tirzepatide (TZP, GLP1R-GIPR co-agonist) and efruxifermin…
3D whole-brain imaging of parenchymal/vascular amyloid plaque architecture during disease progression in a transgenic mouse model of Alzheimer’s disease
Background & Aim: Alzheimer’s disease (AD) is histologically defined by accumulation of Abeta (Aβ) plaques in the brain. Age and gender are important factors in AD pathology. To develop more effective interventions, preclinical studies should therefore consider these factors in…